Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the Cowen & Co. Annual Health Care Conference

Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the Cowen
                     & Co. Annual Health Care Conference

PR Newswire

SAN DIEGO, Feb. 28, 2013

SAN DIEGO, Feb. 28, 2013 /PRNewswire/ --Orexigen® Therapeutics, Inc. (Nasdaq:
OREX) today announced that management will present a company overview at the
Cowen & Co. Annual Health Care Conference in Boston. The presentation is
scheduled for Monday, March 4, 2013 at 3:30 p.m. Eastern Time. To listen to
the live webcast or a replay of the presentation, please visit the Investor
Relations section of the Company's Web site at www.orexigen.com. A replay will
be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the
treatment of obesity. The Company's lead product candidate is Contrave®, which
has completed Phase III clinical trials and for which a New Drug Application
has been submitted and reviewed by the FDA. The Company has also reached
agreement with the FDA on a Special Protocol Assessment for the Light Study,
the Contrave cardiovascular outcomes trial. The Company's other product
candidate, Empatic™, has completed Phase II clinical trials. Further
information about the Company can be found at www.orexigen.com.

Orexigen Contact:                                     Media Contact:
McDavid Stilwell                                      Denise Powell
VP, Corporate Communications and Business Development WCG
(858) 875-8629                                        (510) 703-9491

SOURCE Orexigen Therapeutics, Inc.

Website: http://www.orexigen.com
 
Press spacebar to pause and continue. Press esc to stop.